Clinical trials: SBS - Short Bowel Syndrome

Short Bowel Syndrome

Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome

• Completed
• Age: 6 weeks to 18 months
• Phase 1
• Vaccines
• Pill or oral medicine
• Results posted

Rotavirus infection is a common pediatric illness and is the leading cause of severe acute gastroenteritis (vomiting and diarrhea) in infants and young children.

Trial name

NCT00767364

Testing

Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)

Where

3 sites in United States

Volunteers

8 people, healthy volunteers welcome

Sponsor

Children's Hospital of Michigan